Search and Find
Service
Preface
6
Contents
8
Contributors
12
Part I:Normal Sexual Function
20
Chapter 1: Functional Anatomy of the Male Sex Organs
21
Introduction
21
Penis
21
Skin and Fascia
21
Tunica Albigunea
22
Corpora Cavernosa and Spongiosum
23
Associated Musculature
24
Penile Vascular Anatomy (Fig. 1.2)
24
Lymphatics
26
Innervation
26
Urethra (Fig. 1.3)
26
Testis
27
Epididymis
28
Vas Deferens
28
The Prostate
29
Seminal Vesicles
29
References
29
Chapter 2: Functional Anatomy of the Female Sex Organs
31
Introduction
31
General Structural Relationships
31
External Genital Anatomy
32
Clitoris
32
Bulbs
34
Labia Majora
35
Labia Minora
35
Urethra
36
Blood Supply of the External Genitalia
37
Innervation of the External Genitalia
37
Internal Genital Anatomy
38
Vagina
38
Uterus
39
Uterine Corpus (or Body)
39
Cervix
40
Ovaries and Uterine Tubes
40
Blood Supply of the Internal Genitalia
40
Innervation of the Internal Genitalia (see Fig. 2.12)
40
References
41
Chapter 3: Physiology of Libido
42
Introduction
42
Sexual Arousal
42
Sexual Desire
45
Sexual Reward
46
Sexual Inhibition
47
Conclusions
47
References
48
Chapter 4: Physiology of Orgasm
51
Introduction
51
Definitions of Orgasm
51
Common Features of Orgasm in Males and Females
52
Mental Experience
52
Cardiovascular Phenomenon
52
Pelvic Musculature Contractions
52
Rectal Sphincter Contractions
53
Activation or Deactivation of Areas in the Brain
53
Facial Grimacing
53
Hyperventilation
54
Vocalizations
54
Release of Prolactin and Oxytocin
54
Differences Between Female and Male Orgasms
54
Female Orgasm
54
Uterine Contractions
55
Typologies of Female Orgasm
56
Female Orgasms with Urethral Emission
56
Objective Signs of Orgasm in Women
56
Specific Brain Activity During Female Orgasm
57
The Male Orgasm
57
The Male Orgasm with Ejaculation of semen
57
The Male Orgasm Without Ejaculation of Semen
57
The Post Ejaculatory Refractory Time (PERT)
58
Orgasms Induced by Prostatic Massage
58
Specific Brain Activity During Male Orgasms
58
Typology of Male Orgasms
59
Special Considerations
59
Can We Tell When Someone is Faking an Orgasm?
59
Orgasm and Enhancing its Intensity of Pleasure
59
Female Orgasm and Reproduction
60
Female Orgasm After the Menopause
60
Male Orgasm with Aging
61
Postorgasmic Illness Syndrome
61
Do Orgasms have Health Benefits Other than Pleasure?
61
Addendum
65
References
62
Chapter 5: Physiology of Female Genital Sexual Arousal
66
Introduction
66
Physiology
68
Central Factors in Female Sexual Arousal
68
Peripheral Factors in Female Sexual Arousal
69
Sex Steroid Hormones and Female Genital Sexual Arousal
69
Androgens: Physiology and Pathophysiology
70
Androgens: Clinical Data
71
Estrogens/Progestins: Physiology and Pathophysiology
72
Estrogens/Progestins: Clinical Data
73
Clinical Female Genital Sexual Arousal Disorder Syndrome Associated with Low Estradiol
73
Neurotransmitters and Female Genital Sexual Arousal
74
Vascular Blood Flow
75
Summary
76
References
76
Chapter 6: Physiology of Erection
84
Introduction
84
Neurological Regulation of Erectile Function
84
Cerebral Control of Penile Erection
84
Autonomic Control of Penile Erection
85
Somatic Nervous System and Penile Erection
85
Tissue Level Mechanisms of Penile Erection
85
Molecular Mechanisms of Penile Erection
86
Penile Detumescence
88
Tissue Level Mechanisms of Penile Detumescence
88
Neuronal Regulation of Penile Detumescence
88
Molecular Mechanisms of Penile Detumescence
88
Psychological Factors and Penile Detumescence
89
Endocrine Factors and Penile Erection
90
Conclusion
90
References
90
Chapter 7: Physiology of Ejaculation
92
Introduction
92
Peripheral Anatomical Organization
92
Organs Participating in Emission
93
Epididymis
93
Ductus (or Vas) Deferens
93
Seminal Vesicles
93
Prostate Gland
93
Bulbo-Urethral (or Cowper’s) Glands
93
Organs Participating in Expulsion
94
Bladder Neck and Urethra
94
Striated Muscles
94
Neural Pathways
94
Afferents
94
Efferents
94
Central Nervous System Network
96
Spinal Organization
96
Supraspinal Organization
96
Neurochemical Regulation
98
Dopaminergic Control
98
Serotonergic Control
99
Oxytocinergic Control
99
Human Brain Functioning
100
The Trigger for Expulsion
100
References
102
Part II:Disorders of Sexual Function
105
Chapter 8: Classifying Female Sexual Dysfunction
106
Introduction
106
Historical Overview of the Development of Classification of FSD
107
The DSM System
107
Definitions Reconsidering the DSM Definitions
108
The First Consensus Conference
108
Circular Model Versus a Linear Model and the Second Consensus Conference
108
DSM-V a Suggestion for New Definitions
112
DSM-V
112
Sexual Desire and Arousal Disorders
114
Sexual Aversion Disorder (SAD)
114
Female Orgasmic Disorder (FOD)
114
Dyspareunia
115
Conclusion
115
References
115
Chapter 9: Hypoactive Sexual Desire Disorder
117
Diagnosis
117
Theoretical Models of Sexual Desire
118
Assessment of HSDD (Table 9.2)
121
Differential Diagnosis
122
HSDD Prevalence in Epidemiological Studies
125
Factors Implicated with Sexual Desire
125
Biological Factors
125
Psychological Factors
126
Relationship
127
Cancer
127
Prevalence of Low Desire and HSDD in Cancer Patients
128
Direct Effects of Cancer on HSDD: Biological, Psychological, and Relational
128
Biological
128
Psychological Factors
128
Relational Factors
129
Effect of Cancer Treatment on HSDD
130
Chemotherapy
130
Radiation Therapy
130
Breast Conservation
131
Oophorectomy
131
Conclusions
132
References
133
Chapter 10: Disorders of Female Sexual Arousal
136
Disorders of Female Sexual Arousal
136
Definitions and Problems
137
Diagnostic Criteria for Female Sexual Arousal Disorder
137
Models of Sexual Response
137
Problems with the DSM conceptualization of FSAD
138
Proposed Criteria for the DSM-V
139
Epidemiology
139
Lifetime Prevalence of FSAD
139
Prevalence of FSAD in Cancer Patients
140
Correlates of FSAD
141
Physiological Correlates
141
Physiological Considerations for Cancer Patients
142
Psychological Correlates for FSAD
143
Psychological Considerations for Cancer Patients
143
FSAD in Partners of Patients
145
Assessment
145
Clinical Assessment of FSAD
146
Treatment Overview of FSAD
148
Biological Interventions
148
Topical Lubricants
148
Vasoactive Agents
149
Central Nervous System Acting Agents
149
Hormonal Agents
150
Psychological Interventions
150
Persistent Genital Arousal Disorder
151
Conclusion
152
References
153
Chapter 11: Disorders of Female Orgasm
158
Introduction
158
Definitions of Female Orgasm Disorder
158
The Prevalence of Female Orgasmic Disorder
159
The Impact of Cancer on Women’s Sexual Health
160
Effects of Specific Cancer Treatments on Orgasm Function
161
The Treatment of Female Orgasmic Disorder
162
Psychological Approaches (Table 11.1)
162
Directed Masturbation
162
Anxiety Reduction Techniques
165
Other Techniques
166
Pharmacological Approaches
166
Conclusion
170
References
170
Chapter 12: Sexual Pain Disorders
173
Introduction
173
Classification of Sexual Pain Disorders
173
Sexual Pain Disorders
175
Pain Related to a Specific Disorder
175
Vulvodynia
175
Epidemiology
176
Etiology
176
Psychosocial Factors
177
Assessment
178
Treatment
179
Dyspareunia in Postmenopausal Women
181
Vaginismus
182
Sexual Pain Disorders in Men
184
Dyspareunia and the Cancer Patient
184
Treatment-Related Side Effects
184
Treatment of Cancer-Related Sexual Pain
185
Summary
186
References
186
Chapter 13: Erectile Dysfunction: Prevalence and Pathophysiology
193
Introduction
193
Epidemiology of Erectile Dysfunction
193
Pathophysiology of Erectile Dysfunction
195
Overview
195
Ageing
195
Vascular Disease
197
Endocrine Factors
198
Neurological Factors
199
Conclusions
199
References
199
Chapter 14: Androgen Deficiency
204
Definition
204
Physiology of Hypothalamus-Pituitary-Gonadal Axis
204
Causes of Hypogonadism
206
Effects of Hypogonadism
208
Bone
208
Body Composition
209
Cognition and Mood
209
Metabolic Effects
209
Cardiovascular Effects
210
Sexual Function
211
Diagnosis of Hypogonadism
211
Treatment
212
Androgen Deficiency in the Female Patient
213
Physiology of Hypothalamic-Pituitary-Ovarian (HPO) Axis
213
Causes of Hypogonadism
214
Hypogonadotropic Hypogonadism
214
Eugonadotropic Hypogonadism
216
Hypergonadotropic Hypogonadism
216
Effects of Androgen Deficiency in Women
218
Diagnosis of Androgen Deficiency in Women
219
Treatment of Androgen Deficiency in Women
219
Conclusions
221
References
221
Chapter 15: Peyronie’s Disease
225
Definition
225
History
225
Etiology and Molecular Mechanisms
225
Evaluation of the PD Patient
226
Peyronie’s Disease Following Radical Prostatectomy
229
Nonsurgical Therapy for Peyronie’s Disease
229
Oral Therapies
231
L-Arginine
231
Pentoxifylline
231
Colchicine
231
Potassium Para-Aminobenzoate
232
Transdermal Agents
232
Intralesional Therapies
233
Steroids
233
Collagenase
233
Verapamil
233
Interferon
234
Penile Traction Devices
234
Surgical Treatment of Peyronie’s Disease
234
Tunica Albuginea Plication
235
Peyronie’s Plaque Incision/Partial Excision and Grafting
238
Straightening with Penile Prosthesis
240
References
240
Chapter 16: Disorders of Ejaculation and Male Orgasm
243
Introduction
243
The Anatomy and Physiology of the Ejaculatory Response
244
Premature Ejaculation
246
Introduction
246
Defining Premature Ejaculation
247
Epidemiology of Premature Ejaculation
250
Classification of Premature Ejaculation
250
The Aetiology of Premature Ejaculation
251
Premature Ejaculation and Performance Anxiety
252
Premature Ejaculation and Co-Morbid ED
253
Premature Ejaculation and Other Sexual Dysfunctions
253
Premature Ejaculation and Partner Sexual Dysfunction
253
Premature Ejaculation and Hyperthyroidism
254
Premature Ejaculation and Chronic Prostatitis
254
Delayed Ejaculation, Anejaculation, and Anorgasmia
255
Definition, Terminology, and Characteristics of Men with Delayed Ejaculation
255
Terminology and Definition
255
The Prevalence of Delayed Ejaculation and Characteristics of Men with DE
256
Pathophysiologies Commonly Leading to Ejaculatory Disorders, Including DE
257
Congenital Disorders
257
Traumatic Damage
257
Infective Disorders
257
Neurological Disorders
257
Male Pelvic Cancers
258
Prostate Cancer
258
Rectal Carcinoma
258
Testicular Cancer
259
Spinal Cord Injury
259
Psychological Aetiologies of Delayed Ejaculation
260
Conclusion
261
References
261
Chapter 17: Priapism
267
Background
267
Epidemiology of Priapism and Patient Populations at Risk
268
Diagnosis of Priapism
269
Pathophysiology of Priapism
271
Ischemic Priapism
271
Nonischemic Priapism
271
Stuttering Priapism
272
Medical Management
272
Surgical Management
276
Priapism and Cancer
282
References
284
Part III:Patient Assessment
287
Chapter 18: The Sexual Health Interview: Male
288
Introduction
288
Background Review
288
Helping Communication About Sex Between Patients and Physicians
290
Enhancing the Opportunity
291
Getting Started
292
Preparing the Patient
293
Taking a Sexual History from the Man
293
Erectile Function
294
General Comments
296
Conclusions
296
References
296
Chapter 19: The Sexual Health Interview: Female
298
Introduction
298
Epidemiology and Rationale
298
Sexual Problems in Women with Cancer
299
Need for Improved Sexual Health Dialogs
299
Patient Barriers to Sexual Health Dialogs
300
Physician Barriers to Sexual Health Discussions
300
Detection of Hypoactive Desire and Related Female Sexual Problems
300
Barriers to Sexual Health Dialogs in Female Cancer Patients
301
Physicians’ Desire for Sexual Health Education
301
Models for the Female Sexual Response
302
The Female Sexual Disorders: An Overview of Classification
303
Understanding Sexual Desire and its Components
303
Organizing a Biopsychosocial Approach to Sexual Dysfunction
303
The Three Windows Approach to Understanding Biopsychosocial Factors
304
Optimal Sexual History Taking
304
Screening and Detection of Sexual Problems
304
The Screening Sexual History
304
Screening with a “Ubiquity Statement”
305
The Screening Sexual History in Patients with Cancer
306
Developing the Narrative Thread
306
The Sexual Problem Interview
306
Language
307
Responding to Emotions
307
Using Patient-Centered Dialog to Explore Sexual Problems
308
Discussing Specific Sexual Practices
308
Essentials of a Complete Sexual History
309
Use of Questionnaires
309
Partner Issues
309
Empathic Delineation and Reframing Problems
310
The Interview as a Therapeutic Intervention
310
The P-LI-SS-IT Model
310
Conclusions
311
References
311
Chapter 20: Communication About Sexuality and Cancer
313
Introduction
313
Background Prevalence of Non-Communication
313
Who Should Communicate?
314
Barriers to Communication
314
Attitudes of Staff
314
Communicating with Patients
315
Communication with Partners
315
Communication with Families
316
Language Barriers
316
Communication with LGBT Individuals
317
Ethnicity
317
Disability
318
Barriers Related to Location
318
Clinician Education
319
Patient Information
319
Information to Public
320
Research
320
Conclusions
320
References
320
Chapter 21: Validated Questionnaires in Female Sexual Function Assessment
323
Introduction
323
Using Psychometrics to Evaluate an Instrument
323
Female Sexual Function Assessment Instruments (Tables 21.1–21.4)
324
Sexual Activity Questionnaire (SAQ)
324
Use in Cancer Populations
326
Sexual Function – Vaginal Changes Questionnaire (SVQ)
329
Use in Cancer Populations
329
The Female Sexual Function Index (FSFI)
329
Use in Cancer Populations
330
Derogatis Interview for Sexual Functioning (DISF/DISF-SR)
330
Use in Cancer Populations
331
Derogatis Sexual Functioning Inventory (DSFI)
331
Use in Cancer Populations
332
Brief Index of Sexual Functioning – Women (BISF-W)
332
Use in Cancer Populations
332
Changes in Sexual Functioning Questionnaire (CSFQ)
333
Use in Cancer Populations
333
Golombok-Rust Inventory of Sexual Satisfaction (GRISS)
334
Use in Cancer Populations
334
McCoy Female Sexuality Questionnaire (MSFQ)
334
Use in Cancer Populations
335
Other Measures of Female Sexual Functioning
335
Sexual Satisfaction Assessment Instruments
335
The Global Measure of Sexual Satisfaction (GMSEX)
336
The Index of Sexual Satisfaction (ISS)
337
The Pinney Sexual Satisfaction Inventory (PSSI)
337
The Female Sexual Distress Scale (FSDS)
337
The Sexual Satisfaction Scale for Women (SSS-W)
338
Summary
338
References
339
Chapter 22: Validated Questionnaires in Male Sexual Function Assessment
344
Introduction
344
Symptoms Scales and Questionnaires
344
Comprehensive Male Sexual Dysfunction Scales
345
Golombok Rust Inventory of Sexual Satisfaction
345
International Index of Erectile Function
346
Delayed Ejaculation Scales-Male Anorgasmia
346
Male Sexual Health Questionnaire
346
Premature Ejaculation Measures
347
Premature Ejaculation Profile
347
Index of Premature Ejaculation
347
Premature Ejaculation Diagnostic Tool
347
Treatment Satisfaction Scales
348
Treatment Satisfaction Scale
348
Erectile Dysfunction Inventory for Treatment and Satisfaction
348
Psychological and Interpersonal Relationship Scale
349
Sexual Quality of Life Scales
349
Sexual Life Quality Questionnaire
349
Self-Esteem and Relationship Questionnaire
349
Sexual Quality of Life: Male
350
Cancer-Specific Scales and Validation Data in Cancer Patients
350
Expanded Prostate Cancer Index Composite/UCLA Prostate Cancer Index
350
Validation of Scales in a Cancer Population
351
Summary and Conclusions
351
Appendix
351
Medical, Psychosocial, and Sexual Assessment Questionnaire
351
Erection
352
Libido/Interest
352
Ejaculation/Orgasm/Satisfaction
352
Satisfaction
352
Previous Consultations
352
References
353
Chapter 23: Evaluation of the Female with Sexual Dysfunction
355
Examination of the Female Cancer Patient
355
Specialized Testing for the Sexual Health Assessment
356
Laboratory Testing
356
Sonography
357
Advanced Testing
357
Vulvoscopy
357
Vaginal Photoplethysmography
357
Functional Magnetic Resonance Imaging
357
Quantitative Sensory Testing
358
Perinometry
358
Psychosexual Assessment After Cancer Diagnosis and Treatment
358
Surgical Considerations
358
Radiation Therapy Considerations
359
Chemotherapy Considerations
359
Hormone Therapy Considerations
359
Sexuality and Relationship Considerations
359
Other Psychological Considerations
359
Issues of Sexuality
360
Conclusions
360
References
360
Chapter 24: Evaluation of Male Sexual Dysfunction
361
Male Sexual Dysfunctions and Cancer Survivors
361
Changing Paradigms in the Evaluation of Erectile Dysfunction
362
Questionnaires and Sexual Function Symptom Scores
365
Questionnaires and Cancer Survivors
365
Medical, Sexual, and Psychosocial History
366
Medical History
366
Sexual History
367
Psychosexual History for the Nonmental Health Professional
368
Physical Examination
369
Laboratory Testing
369
Hormonal Evaluation
370
Cancer Survivors and Gonadal Status
371
Review of Findings
372
Specialist Consultation and Referral
372
Vascular Evaluations of Erectile Dysfunction
374
First-Line Evaluation of Penile Blood Flow
374
Second-Line Evaluations of Penile Blood Flow
374
Penile Doppler Sonography
374
Recommendations of the ICSM on Penile Vascular Testing
377
Selective Internal Pudendal Arteriography
377
Nocturnal Penile Tumescence
379
Hypoactive Sexual Desire
379
Ejaculatory Disorders
380
Cancer Survivors and Ejaculatory Dysfunction
381
Specific Ejaculatory Dysfunctions
382
Conclusions
383
References
383
Chapter 25: The Impact of Cancer on the Partner’s Sexuality
387
Introduction
387
What is Sexuality? Concepts of Human Sexuality
387
Human Sexuality from a Systems Perspective: The Four Component Sexual Model
388
The Impact of Cancer on Sexuality from a Systems Perspective
389
Impact of Cancer on the Partner’s Sexuality from a Systems Perspective
390
Impact of Male Sexual Dysfunction on Partners
392
Impact of Female Sexual Dysfunction on Male Partners
394
Impact of Cancer Diagnosis and Treatment on the Partner’s Sexuality
394
Psychological Impact of Cancer on Partner
394
Sexual and Intimacy Effects of Cancer on the Partner
395
Psychosocial Impact on the Partner of Men with Prostate Cancer
396
Impact on the Partner of Women with Breast Cancer
397
Clinical Intervention of Health Care Professionals
397
Conclusion
398
References
398
Chapter 26: Gay and Lesbian Patients with Cancer
400
Introduction
400
Health Care Provider Assumptions
400
Special Considerations for Lesbians
401
Special Considerations for Gay Men
401
Prostate Cancer
401
Colorectal Cancer
402
Attitudes of Health Care Providers to Gay/Lesbian Patients
402
Homophobia
402
Heterosexism
403
Disclosure of Same Sex Attraction or Relationship
403
How Oncology Care Providers Can Help
404
PLISSIT Model
404
Conclusion
405
References
405
Part IV:Cancer and Sex
407
Chapter 27: The Impact of a Cancer Diagnosis on Sexual Health
408
Introduction
408
The Psychological Response to a Cancer Diagnosis and Its Impact on Sexual Functioning
409
Partners Perception of Diagnosis and Affects on Sexuality (Table 27.2)
410
The Lack of Discussion of Sexuality at Diagnosis (Table 27.3)
412
Conclusion
414
References
414
Chapter 28: Breast Cancer
416
Breast Cancer Epidemiology and Population Data on Sexuality
416
The Interactive Biopsychosocial Model Applied to Sexualityand Breast Cancer
418
Sexuality and the Breast Cancer Care Continuum
420
Breast Cancer Risk Factors and Sexuality
420
Breast Cancer Screeningand Sexuality
421
Average-Risk Women Screening Guidelines
421
Very High-Risk Women Screening Guidelines
421
Diagnosis
425
Treatment
426
Surgery
426
Chemotherapy
429
Adjuvant Chemotherapy
431
Taxanes
431
Trastuzumab/Herceptin
436
Radiation
436
Hormonal Therapy: Pre- and Perimenopausal Women
436
Aromatase Inhibitors
438
Zoledronic Acid
438
Adjuvant Hormonal Therapy: Postmenopausal Women
439
Targeted Palliative Therapies
439
Bevacizumab
440
Lapatinib
440
Complications from Cancer Therapy
440
Treatment of Sexual Problems in Breast Cancer Survivors
441
Vaginal Dryness
441
Pain with Intercourse
443
Vaginal Stenosis
445
Vaginismus
446
Low or Absent Sexual Desire and Difficulty with Arousal and Orgasm
447
Role of Psychotherapy, Sex Therapy, Couples and Marital Therapy, Psychiatric Medications
448
Cancer Survivorship and Health Maintenance
450
Bone Health
450
Cardiovascular Health
451
Key Research Questions and Needs to Advance Care of Sexuality Issues in People with Breast Cancer or Elevated Breast Cancer Risk
451
References
451
Chapter 29: Gynecological Cancers
457
General Considerations
457
The Etiopathogenetic Framework of Sexual Dysfunction in Genital Cancer Patients
458
Cancer of the Vulva
458
Impact of the Disease and Treatment Procedures
458
Prevalence and Incidence of Sexual Dysfunction and Contributing Factors
458
Cancer of the Vagina
459
Impact of the Disease and Treatment
459
Prevalence, Incidence of Sexual Dysfunction, and Contributing Factors
459
Cancer of the Cervix
459
Impact of the Disease and Treatment
459
Prevalence, Incidence of Sexual Dysfunction, and Contributing Factors
460
Quality of Life Studies
460
Differences Between Treatment Procedures (Table 29.1)
460
Specific Physical Findings and Sexual Dysfunction (Table 29.2)
462
Contributing Factors
464
Endometrium Carcinoma
466
Impact of the Disease and Treatment
466
Prevalence, Incidence of Sexual Dysfunction, and Contributing Factors
466
Cancer of the Ovaries
467
The Impact of the Disease and Treatment
467
Prevalence, Incidence of Sexual Dysfunction, and Contributing Factors
467
Assessment of Sexual Functioning
468
Therapy
468
Psychological Interventions
469
Local Nonhormonal and Mechanical Interventions
470
Lubricants
470
Vaginal Dilatation
471
Hormonal
471
Local Estrogen
471
Summary and Conclusion
472
References
473
Chapter 30: Pelvic Surgery for Urological Cancers
476
Anatomy of Erectile Function
476
Arterial Supply
476
Accessory Pudendal Arteries
476
Venous Drainage
477
Neuroanatomy
477
Corporal Smooth Muscle
478
Erectile Dysfunction Prevalence
478
Erectile Dysfunction Pathophysiology
479
Neural Trauma
479
Corporal Smooth Muscle Alterations
480
Venous Leak
481
Radical Prostatectomy-Associated Sexual Dysfunctions
481
Anejaculation
481
Orgasm Alterations
481
Peyronie’s Disease
482
Penile Length Alterations
483
References
484
Chapter 31: Pelvic Radiation in Men
488
Introduction
488
Methods for the Evaluation of Erectile Dysfunction
488
Definition of Potency
488
Etiology of Postradiation Erectile Dysfunction
489
Incidence of Erectile Dysfunction After Radiotherapy for Prostate Cancer
489
Incidence of Erectile Dysfunction After External-Beam Radiotherapy
489
Incidence of Erectile Dysfunction After Brachytherapy
489
Incidence of Erectile Dysfunction After Radiotherapy for Bladder Cancer
492
Incidence of Erectile Dysfunction After Radiotherapy for Penile Cancer
493
Incidence of Erectile Dysfunction After Radiotherapy for Testicular Cancer
494
Incidence of Erectile Dysfunction After Radiotherapy for Colorectal Cancer
496
Ejaculatory and Other Sexual Dysfunctions
497
Therapy of Postradiation Erectile Dysfunction
497
Prevention of Postradiation Erectile Dysfunction
497
Conclusion
498
References
498
Chapter 32: Pelvic Radiation in Women
502
Radiotherapy for Cancer in the Pelvis
502
Late Effects of Radiotherapy
503
Assessment of Sexual Function
505
Psycho-sexual Effects of Pelvic Radiation
506
Sexual Problems After Pelvic Radiation
507
Gynaecological Cancer
507
Rectal Cancer
512
Anal Cancer
514
Bladder Cancer
515
Intervention for Female Sexual Dysfunction
516
Premature Ovarian Failure
516
Hormone Replacement Therapy
516
Post-irradiation Vaginitis/Vaginal Mucositis
516
Oestrogen
516
Benzydamine
517
Hyperbaric Oxygen Therapy
517
Vaginal Dilators
517
Conclusion
518
References
518
Chapter 33: Impact of Chemotherapy and Hormone Therapy on Female Sexual Health
524
Introduction
524
Impact of Chemotherapy on Female Sexual Health
525
Impact of Hormone Therapy on Female Sexual Health
527
Management Strategies for Female Sexual Symptoms Related to Chemotherapy and Hormone Therapy
528
References
530
Chapter 34: Impact of Androgen Deprivation Therapy on Men’s Sexual Health
534
Introduction
534
Role of Testosterone on Male Sexual Health
535
Physiology of Testosterone
536
Hypothalamus-Pituitary-Testis Axis
536
Production of Androgens by the Adrenal Gland
536
Mechanism of Action of Androgen Deprivation Therapy
537
Medical Castration
537
Surgical Castration
538
Antiandrogens
538
Inhibition of Androgen Synthesis
538
Androgen Deprivation Therapy Effects on Sexual Function
538
Erectile Function
539
Ejaculation
540
Libido
540
Genital Changes
541
Assessment of Patients on Androgen Deprivation Therapy
541
Therapeutic Strategies for Patients on Androgen Deprivation Therapy
542
Intermittent Versus Continuous Androgen Deprivation Therapy
542
Penile Rehabilitation
543
Conclusions
543
References
543
Chapter 35: Colorectal Cancer
547
Overview of Treatment of Colon and Rectal Cancer
547
The Impact of Colorectal Cancer Diagnosis on Psycho-Sexual Functioning
548
The Impact of a Stoma on Sexual Functioning
549
The Impact of Treatment of Rectal Cancer on Male Sexual Functioning (Table 35.1)
550
The Impact of Treatment of Rectal Cancer on Female Sexual Function
553
Counseling and Treatment
555
References
556
Chapter 36: Stem Cell Transplant
559
Description of HSCT
559
Challenges from the Start of HSCT
560
Challenges After HSCT
560
Treatment Factors Contributing to Sexual Dysfunction
561
Chemotherapy and TBI
561
Graft Versus Host Disease and Sexuality
562
The Interaction of Physiological, Behavioral, Psychological, and Social Effects on Sexuality After HSCT
562
Other Issues Contributing to Sexual Function
563
Psychological Factors Contributing to Sexual Dysfunction
563
Determining Who Is at Greater Risk for Sexual Dysfunction After HSCT
564
Evaluating Sexual Functioning After HSCT
565
Medical Treatment Options
566
Behavioral Treatment Options
568
Research Needs in the HSCT Population
570
Conclusions
570
References
570
Chapter 37: Sexual Health in the Terminally III
574
Introduction
574
Sexuality and Intimacy in Cancer and Palliative Care
574
Experiencing a Cancer Diagnosis
574
Effects of Cancer Treatment on Sexuality and Intimacy
575
Treatment Ends: Now What?
575
Sexuality in the Palliative or Terminal Settings
575
Discussing Patient Sexuality in Palliative and Terminal Care
576
The Why of Sex
577
The Direct Physical Benefits of Sexual Expression
577
The How of Sex in the Palliative Stage?
578
Various Reactions and Topics in the Palliative–Terminal Phase
578
The Role of the Medical and Helping Professionals
579
Various Organizational Problems and Solutions
579
Introducing Discussions About Patient Sexuality and Intimacy
579
Creating Space/Room for Undisturbed Intimacy
580
Various Physical Problems and Solutions
580
Conclusions
583
References
583
Part V:Treatment Strategies
585
Chapter 38: Survivorship: An Overview
586
Introduction
586
Definition of Survivorship
586
Current Focus on Survivorship
587
A National Survivorship Agenda
587
Challenges of Survivorship
587
Models of Survivorship Care
589
Current and Evolving Clinic Models
589
Providing a Care Plan for Survivorship
590
Cancer and Sexuality: Where Does Survivorship Fit In
592
Oncology Clinician Practice Related to Sexual Health
592
Sexual Health as an Exemplar for Survivorship Care
593
Improving Clinical Practice
593
Institutional Program Development
593
National Advocacy
594
References
594
Chapter 39: Nutriceuticals in Sexual Health
597
Introduction (Part 1): Heart Health=Sexual Health (Ageless Education)
597
Introduction (Part 2): Heart Health=Sexual Health and Promoting Probability
598
Conclusion
614
References
615
Chapter 40: Medical Treatments for Sexual Problems in Women
621
Introduction
621
Iatrogenic Menopause
621
Fertility Preservation
622
Embryo Cryopreservation
622
Cryopreservation of Mature Oocytes
622
Cryopreservation of Immature Oocytes After In Vitro Maturation (Without Gonadotropin Stimulation)
623
Gonadotropin-Releasing Hormone Analogue Treatment
623
Cryopreservation of Ovarian Tissue
623
Medical Therapies of Sexual Disorders in Cancer Survivors
623
Hormone Therapy
625
Systemic
625
Estrogens
626
Estrogen and Progestins
626
Estrogen/Androgen Combination Therapy
626
Transdermal Testosterone Specifically for Women
627
Synthetic Steroids
627
Topical Hormonal Therapies
628
Nonhormonal Central Nervous System Acting Drugs
628
Antidepressants in Sexual Problems and Depression
628
Bupropion
628
Synergy Between Antidepressants and HRT in Addressing Sexual Disorders
629
Antidepressant Drugs in the Treatment of Menopausal and Sexual Symptoms
630
Nonhormonal Topical Treatments
630
Vasoactive Agents in Women
630
Botulin Toxin
630
Future Treatment Options
631
Flibanserin
631
Psychosocial Interventions
632
Conclusion
632
References
633
Chapter 41: Surgical Treatments for Sexual Problems in Women
636
Introduction
636
Vulvar Anatomy
636
Terminology
637
Vestibulodynia
637
Clitoral Phimosis
638
Perineoplasty
638
Bartholin’s Gland
639
Conclusions
639
References
640
Chapter 42: Sex Therapy in Female Sexual Dysfunction
641
Introduction
641
Gender Differences withSexual Function After Cancerand Physician Impact withPatient Response
641
Clinical Considerations for Diagnosis and Treatment of Women with Genital and Breast Cancer
642
Psychosocial Implicationsof Cancer on Women and Their Sexual Function
643
Mental Health Interventions (Table 42.1)
644
Support Groups
644
Hypnotherapy
644
Psychotherapy
644
Cultural Differences in Sexual Functioning for Women with Cancer
646
References
647
Chapter 43: Erectile Function Preservation for Men with Cancer
649
Introduction
649
Erectile Tissue Structure and Function
650
Cancer Treatments and Erectile Tissue Damage
650
Pelvic Surgery
650
Pelvic Radiation
652
Androgen Deprivation Therapy
652
Erectile Tissue Damage and Erectile Dysfunction
653
Erectile Tissue Preservation and Cancer Treatments
655
Erectile Tissue Preservation: Animal Study Data (Table 43.1)
656
Erectile Tissue Preservation: Human Study Data (Table 43.2)
659
Summary
662
References
663
Chapter 44: Erectile Dysfunction: Pharmacological Therapy
666
Introduction
666
Historical Review of Modern Erectile Dysfunction Pharmacotherapy
666
Goals of Pharmacological Therapy
667
Oral Agents
669
Phosphodiesterase 5 Inhibitors
669
Sildenafil
669
Tadalafil
673
Vardenafil
674
Nonarteritic Ischemic Optic Neuropathy
675
Sudden Sensorineural Hearing Loss
675
PDE5 Inhibitors Failures
675
Dopamine Receptor Agonists
676
Apomorphine
676
Adrenergic Receptor Antagonists
676
Yohimbine
676
Phentolamine
677
Serotonergic Receptor Agonists
677
Trazodone
677
Other Oral Agents
677
Transdermal Agents
677
Intracavernosal Agents
677
Alpha-Adrenoreceptor Blocking Agents
678
Phentolamine
678
Phosphodiesterase Inhibitor
678
Papaverine
678
Adenylate Cyclase Activators
678
Alprostadil (Prostaglandin E 1)
678
Other Intracavernosal Agents
679
Intracavernosal Agent Combinations
679
Important Aspects of Intracavernous Injection Therapy
680
Transurethral Therapy
681
References
682
Chapter 45: Erectile Dysfunction: Devices
688
Introduction
688
Vacuum Erection Devices
688
Penile Implants
691
Noninflatable Penile Implants
692
Inflatable Penile Implants
694
Conclusion
697
References
697
Chapter 46: The Management of Premature Ejaculation
699
Introduction
699
History of Premature Ejaculation
699
Definition of Premature Ejaculation (Table 46.1)
699
Research of Definition
700
Animal Model of Premature Ejaculation
701
Normal and Abnormal Ejaculation Time
701
Classification of Premature Ejaculation
701
Lifelong Premature Ejaculation
701
Acquired Premature Ejaculation
702
Two New Subtypes of Premature Ejaculation
702
Natural Variable Premature Ejaculation
702
Premature-Like Ejaculatory Dysfunction
703
Genetics of Lifelong Premature Ejaculation
703
Drug Treatment of Premature Ejaculation (Table 46.2)
703
Daily Oral Medication
704
On-Demand Drug Treatment
705
SSRIs
705
Dapoxetine
705
Tramadol
705
PDE5 Inhibitors
706
Topical Anesthetics
706
Inadequate Intracavernous Self-Injection Therapy for PE
706
Psychologic Treatment of Premature Ejaculation
706
Psychotherapy
706
Stop-Start Method
707
The Squeeze Technique
707
Sensate Focus
707
Clinical Interview of Men with Complaints of Premature Ejaculation
707
Relevant Questions for Considering Different Treatment Options
708
Summary
708
References
709
Chapter 47: Testosterone Therapy in the Male Cancer Patient
711
Overview
711
Introduction
712
Testosterone Deficiency and the Prostate Cancer Patient
712
The Origin of the Prohibition Against TTh in Prostate Cancer Patients
712
Historical Experience with Testosterone and Prostate Cancer
713
The Original Report: Huggins and Hodges
713
Historical Experience with T Administration in Men with PCa
713
The Memorial-Sloan Kettering Experience
714
Modern Evidence Regarding Testosterone and the Risk of PCa
714
Natural History
714
Longitudinal Studies of Serum Testosterone and Subsequent Risk of Prostate Cancer
714
Clinical TTh Trials
715
TTh in Men with Prostatic Intraepithelial Neoplasia
715
Prostate Biopsy in Men with Low Testosterone
715
Testosterone Flare and PSA
715
Testosterone Treatment in Men with Prostate Cancer
716
Rationale
716
Testosterone Following Radical Prostatectomy
716
Testosterone Following Other Treatments for PCa
717
TTh in Men with Untreated or Recurrent PCa
717
Current Understanding of the Relationship of PCa and T
717
Conclusions
718
References
718
Chapter 48: Sex Therapy in Male Sexual Dysfunction
721
Introduction
721
Psychological and Sexual Impact on Men and Their Partners
722
The Men
722
The Partners
722
The Relationship
723
Psychosocial Interventions
723
Role of Sex Therapy and Psychotherapy
724
Review of Existing Psychosocial Programs
724
Other Suggestions Regarding Content and Timing of Interventions
725
Conclusion
726
References
727
Chapter 49: Restoring Intimacy in Relationships Affected by Cancer
729
Introduction
729
Prostate Cancer, Intimacy, and the Marital Relationship
729
Psychosocial Interventions Addressing Relationship Intimacy Needs
732
Patient-Focused Psychological Interventions
733
Partner-Focused Psychological Interventions
734
Couple-Focused Psychological Interventions
735
Future Directions
737
Conclusion
738
References
738
Chapter 50: Dating and Disclosure for Cancer Survivors
741
Introduction
741
Theoretical Perspectives on Disclosure
742
Dating and Disclosure in the Context of Cancer
743
Culture as Context
745
Age and Developmental Stage
745
Gender
746
Race/Ethnicity, Socioeconomic Status, and Religion
746
Sexual Orientation and Gender Identity
747
Patient Information and Resources
747
Clinical and Research Implications
749
Conclusion
750
References
751
Index
753
All prices incl. VAT